Table 1.
Characteristics of patients with latent tuberculosis infection
| Characteristic |
Home follow-upa (N=986) |
Clinic follow-upb (N=2932) |
p-valuec | |||
|---|---|---|---|---|---|---|
| N | (%) | N | (%) | |||
| Female |
549 |
(55.7) |
1467 |
(50.0) |
0.002 |
|
| Median age |
22 |
|
24 |
|
<0.001 |
|
| (1st and 3rd quartile) |
(10–31) |
|
(13–35) |
|
|
|
| Age categories: |
|
<0.001 |
||||
| |
< 6 years old |
141 |
(14.3) |
140 |
(4.8) |
|
| 6 to < 18 |
277 |
(28.1) |
967 |
(33.0) |
||
| 18 to < 35 |
399 |
(40.5) |
1085 |
(37.0) |
||
| 35 and older |
169 |
(17.1) |
740 |
(25.2) |
||
| Place of birth: |
|
0.008 |
||||
| |
Latin America |
592 |
(60.0) |
1573 |
(53.7) |
|
| Asia |
243 |
(24.7) |
837 |
(28.6) |
||
| USA |
75 |
(7.6) |
268 |
(9.1) |
||
| Africa |
22 |
(2.2) |
48 |
(1.6) |
||
| Europe |
20 |
(2.0) |
82 |
(2.8) |
||
| Unknown |
34 |
(3.5) |
124 |
(4.2) |
|
|
| Needed translation serviced |
60 |
(6.1) |
176 |
(6.0) |
0.93 |
|
| Patient referral reason: |
|
|||||
| |
TST converters and TB case contactse |
220 |
(22.3) |
229 |
(7.8) |
<0.001 |
| Correction and rehabilitationf |
9 |
(0.9) |
226 |
(7.7) |
|
|
| Postpartum womeng |
59 |
(6.0) |
169 |
(5.8) |
||
| TST+h from screening |
698 |
(70.8) |
2308 |
(78.7) |
||
| Prescribed 9Hi regimen | 555 | (56.3) | 1595 | (54.4) | 0.30 | |
aPatients assigned home-based follow-up with a community health worker and public health nurse.
bPatients with clinic-based follow-up.
cSignificance testing with chi-square test or Wilcoxon rank-sum test.
dPatients who spoke languages other than Spanish, Tagalog, Vietnamese, Cantonese, or Mandarin, and required use of a phone translation service or a family member for communication.
eRecent tuberculin skin test converters and household contacts to active tuberculosis cases.
fPatients from correctional and drug and alcohol rehabilitation facilities.
gWomen treated more than 2 months after delivery of child.
hTST+: Tuberculin skin test positive from routine screening.
i Nine months of isoniazid as opposed to six months of isoniazid.